TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy

Around 50% of cutaneous melanomas harbour therapeutically targetable BRAF V600 mutations. Reliable clinical biomarkers predicting duration of response to BRAF-targeted therapies are still lacking. Recent in vitro studies demonstrated that BRAF-MEK inhibitor therapy response is associated with tumour...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2022-01, Vol.161, p.99-107
Hauptverfasser:	Thielmann, Carl M., Matull, Johanna, Zaremba, Anne, Murali, Rajmohan, Chorti, Eleftheria, Lodde, Georg, Jansen, Philipp, Herbst, Rudolf, Terheyden, Patrick, Utikal, Jochen, Pföhler, Claudia, Ulrich, Jens, Kreuter, Alexander, Mohr, Peter, Gutzmer, Ralf, Meier, Friedegund, Dippel, Edgar, Weichenthal, Michael, Kretz, Julia, Möller, Inga, Sucker, Antje, Paschen, Annette, Livingstone, Elisabeth, Zimmer, Lisa, Hadaschik, Eva, Ugurel, Selma, Schadendorf, Dirk, Griewank, Klaus G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Algorithms Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Tumor - genetics BRAF Confidence intervals Female Humans Immunotherapy Inhibitors Male MEK inhibitors Melanoma Melanoma - drug therapy Melanoma - genetics Metastases Middle Aged Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors Mutants Mutation Mutation - genetics Mutation profiling Patients Progression-Free Survival Promoter Regions, Genetic - genetics Proto-Oncogene Proteins B-raf - antagonists & inhibitors Regression analysis Retrospective Studies Statistical analysis Survival Targeted therapies Telomerase - genetics TERT promoter Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!